Join the Lamictal XR group to help and get support from people like you.
Lamictal XR News
Two Common Antiseizure Medications Do Not Harm Child Neurodevelopment
TUESDAY, Dec. 3, 2024 -- Fetal exposure to two common antiseizure medications (ASMs) does not seem to negatively impact children's neurological development at age 6 years, according to a study pu...
Newer Epilepsy Meds Safe During Pregnancy, Won't Affect Kids' Neurodevelopment
MONDAY, Dec. 2, 2024 – For decades, it's been known that certain older medications women use to control epilepsy seizures can pose risks to a fetus. However, data now suggests that no such risk ...
In Utero Exposure to Certain Antiepileptics Tied to Neurodevelopmental Diagnoses
MONDAY, Nov. 25, 2024 – Exposure to certain antiseizure medications (ASMs) in utero is associated with an increased likelihood of neurodevelopmental diagnoses, according to a study published online...
Lamotrigine, Mexiletine Show Similar Benefits for Nondystrophic Myotonias
WEDNESDAY, Oct. 9, 2024 – Improvements in nondystrophic myotonias symptoms are similar for lamotrigine and mexiletine, according to a study published in the October issue of The Lancet Neurology. ...
FDA Medwatch Alert: Drug Safety Communication: Lamictal (lamotrigine) - Studies Show Increased Risk of Heart Rhythm Problems in Patients with Heart Disease
March 31, 2021 – A U.S. Food and Drug Administration (FDA) review of study findings showed a potential increased risk of heart rhythm problems, called arrhythmias, in patients with heart disease who...
FDA Medwatch Alert: Taro Pharmaceuticals U.S.A., Inc. Issues Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles
January 10, 2020 – Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling one (1) lot of Lamotrigine 100 mg Tablets, Lot # 331771 (expiration date June 2021) in 100 coun...
FDA Medwatch Alert: Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction
ISSUE: The FDA is warning that the medicine Lamictal (lamotrigine) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s i...
FDA Medwatch Alert: Lamotrigine Orally Disintegrating Tablet 200 mg by Impax: Recall - Incorrect Labeling of Blister Cards
ISSUE: Impax Laboratories, Inc. issued a voluntary nationwide retail level recall on August 19, 2016 for one lot of Lamotrigine Orally Disintegrating Tablet (ODT) 200 mg, NDC 0115-1529-08, Lot #...
FDA Approves Lamictal XR (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
RESEARCH TRIANGLE PARK, N.C., April 25, 2011 /PRNewswire/ – GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved Lamictal XR (lamotrigine)...
Further information
Related condition support groups
Seizure Prevention, Seizure Prophylaxis, Epilepsy